What question did this study set out to answer?

The study aims to create a lactylation-related gene signature to predict prognosis and immunotherapy response in triple-negative breast cancer.

May 29, 2026

Prognosis and Immunotherapy Effect of Triple-Negative Breast Cancer by Lactylation-Related Genes and Experimental Validation

Key Points

The study aims to create a lactylation-related gene signature to predict prognosis and immunotherapy response in triple-negative breast cancer.
Analyzed transcriptomic and clinical data from public TNBC cohorts.
Constructed a gene scoring model based on consensus clustering of lactylation-related gene signatures.
Validated findings using quantitative real-time PCR, Western blot, and confocal immunofluorescence microscopy.
High-score group exhibited superior clinical outcomes compared to low-score group.
Improved responses to immunotherapy were observed, associated with immune checkpoint profiles and chemotherapy sensitivity.
Key genes identified include Programmed Cell Death 1 Ligand 2, Immunoglobulin J Chain, and Colony Stimulating Factor 2 Receptor Beta.

Abstract

Background Triple-negative breast cancer (TNBC) is an aggressive subtype of breast malignancy characterized by poor clinical outcomes and limited therapeutic options. The identification of reliable biomarkers for predicting prognosis and immunotherapeutic response remains an urgent clinical need. This study aimed to develop an integrative lactylation-related gene signature to simultaneously evaluate prognostic trajectories and immunotherapeutic sensitivity in TNBC. Methods Transcriptomic and clinical data from public TNBC cohorts were systematically analyzed. Lactylation-related gene signatures were used to stratify patients via consensus clustering. A scoring model was constructed based on differentially expressed genes between clusters, and its associations with immune infiltration, pathway enrichment, drug sensitivity, and clinical outcomes were evaluated. Finally, quantitative real-time polymerase chain reaction, Western blot and Confocal immunofluorescence Microscopy were used to validate the hub genes. Results Significant gene expression differences stratified TNBC patients into high- and low-score groups, with the high-score group demonstrating superior clinical outcomes. These patients also showed better responses to immunotherapy, as indicated by immune checkpoint profiles and chemotherapy sensitivity. Experimental validation confirmed Programmed Cell Death 1 Ligand 2, Immunoglobulin J Chain, and Colony Stimulating Factor 2 Receptor Beta as key molecular nodes. Our scoring model predicts immunotherapy efficacy, and these three genes may represent potential candidates for further therapeutic exploration in TNBC. Conclusions This study establishes a novel lactylation-related gene signature that effectively predicts both prognosis and immunotherapeutic sensitivity in TNBC. The identified hub genes represent promising biomarkers and potential therapeutic targets warranting further investigation.

Ask AI

Helpful

Bookmark

View Full Paper